A continuing need exists for anti-influenza agents effective in the treatment and prevention of influenza A and B virus infections. The compound LY217896 (1,3,4-thiadiazole-2-ylcyanamide) is a water-soluble thiadiazole derivative which possesses broad antiviral activity in vitro and in animal models against orthomyxo-and paramyxoviruses (3, 5, 7) . When administered orally, intraperitoneally, or by aerosol, LY217896 significantly reduced pulmonary viral titers and protected mice against lethal influenza A or B virus challenge (3) . Single intraperitoneal doses of LY217896 were effective in suppressing fever induced by influenza B virus infection of ferrets (3) , and low intraperitoneal doses (3 mg/kg of body weight per day) were effective in reducing lung viral titers following respiratory syncytial virus or parainfluenza virus type 3 infection of cotton rats (7) .
In phase I studies with healthy volunteers, single doses of up to 500 mg were well tolerated and had predictable pharmacokinetics (1) . The maximum concentration in serum averages 0.7 ,ug/ml at a dose of 17 mg and 32.2 pLg/ml at 500 mg, and the plasma drug elimination half-life is about 2 h (1). An initial human trial, in which doses of 50 mg once daily were begun 24 h after challenge with influenza B/Yamagata/88 virus, found that LY217896 administration was not associated with antiviral effects or a reduction in illness (2) . Consequently, the current clinical trial was conducted to determine the prophylactic efficacy of a higher dose of oral LY217896 in experimental influenza A (HlNl) virus infection.
Study design. Healthy males age 18 to 45 years with titers of hemagglutination inhibition (HI) antibody to the challenge virus of .1:8 were recruited for participation. All provided written, informed consent in a form approved by the Institutional Review Boards of the respective institutions and were compensated for participation. Volunteers were confined in an isolation facility for a period of 8 to 9 days during the study as described previously (6) . After an 1-day observation period, subjects were randomly assigned to treatment with oral LY217896 (75 mg per dose) or placebo once each morning for 7 days. After the second drug dose (i.e., 24 h after initiating treatment), they were inoculated intranasally with approximately 107 50% tissue culture infective doses of safety-tested influenza A/Kawasaki/86 (H1N1) virus (0.25 ml per nostril) provided by L. Potash (PRI/DYN Corp., Rockville, Md.).
Daily nasal washings beginning 1 day before virus inoculation were inoculated onto monolayers of Madin-Darby canine kidney (MDCK) cells for isolation of influenza virus by standard techniques. For samples which were positive for virus, once-frozen aliquots (-70°C) were thawed and serial loglo dilutions were titered in quadruplicate monolayers of MDCK cells. Sera obtained 1 day before virus challenge and approximately 3 weeks after challenge were assayed in parallel to determine titers of HI antibody to the challenge virus.
Beginning prior to virus inoculation, each volunteer rated the severity (4-point scale, absent to severe) of 10 symptoms twice daily, in the morning and the late afternoon (6) . Subjects had daily standardized physical assessments by a physician, and oral temperatures were measured four times daily. Fever was defined as the occurrence of an oral temperature of 37.8°C or higher, and administration of acetaminophen was allowed for fever or disabling symptoms. Safety monitoring included routine hematology, blood chemistries, and urinalysis studies done before virus challenge, every other day during the treatment period, and approximately 3 weeks after cessation of therapy. Stool samples were tested for occult blood during drug administration.
Pharmacokinetic studies. The pharmacokinetic profile of LY217896 during the course of experimental influenza virus infection was evaluated by obtaining samples for plasma drug concentrations once each day at designated intervals following dosing. On study days 1 to 7 the interval from the last dose to time of drug sampling was planned to be 0. Although nearly half of the subjects in each of the groups removed from the study reported generalized myalgias on at least one postchallenge inoculation because of day, the occurrence of objectively documented fever was ations. Consequently, 18 infrequent in both groups (Table 1 ). Approximately two-thirds ated subjects were conof the subjects in each group experienced upper respiratory 11 the participating subtract illness on at least two consecutive days, but fewer than ,were 22.0 years in the 15% in each group had a cough persisting for this period of the placebo group. The time ( Table 1) . No differences between the groups were found d to average height (181 in the weights of expelled nasal mucus ( (3) . Similarly, once-daily intraperitoneal administration of low doses (3 mg/kg/day) reduced replication of either respiratory syncytial virus or parainfluenza virus type 3 in cotton rats (7), although 10-fold-higher doses were not active after oral administration. The dose of LY217896 used in this study was well tolerated during short-term administration. In contrast to anecdotal reports of gastrointestinal intolerance during phase I trials, it did not cause diarrhea or gastrointestinal upset. Except for one LY217896 recipient who had guaiac-positive stools on several treatment days, no detectable blood loss in stool samples was found (data not shown). In addition, no adverse effects on formed blood elements, which might suggest depression of bone marrow function, were observed. The only laboratory abnormality conlistently associated with LY217896 administration was increased serum uric acid during the treatment period. Although asymptomatic and usually remaining within the normal range of values, these increases were observed in most volunteers and were possibly related to either decreased clearance of uric acid at the renal level or increased production. Preliminary studies of urinary excretion of uric acid in uninfected volunteers have found evidence for increased production, likely indicating more rapid turnover of dividing cells. The uricogenic effect is dose related and has been described previously for patients receiving thiadiazoles.
In summary, the finding of adverse effects on uric acid metabolism at doses that are not associated with antiviral effects suggests that oral LY217896 is unlikely to have clinically useful anti-influenza virus activity.
